Cellular Therapy Initiative
Cancer therapies have improved dramatically over the last several years, due to the development and discovery of novel therapies resulting from the science and research conducted at AACI cancer centers. Among these are chimeric antigen receptor T-cell (CAR T) therapies and tumor infiltrating lymphocyte (TIL) therapy.
The AACI Cellular Therapy Initiative (CTI) facilitates collaboration between subject matter experts at AACI’s member centers through meetings, webinars, and various working group and task force projects. As the field continues to grow and novel treatments are approved by the U.S. Food and Drug Administration, the mission of CTI is to provide a forum where AACI cancer center CTI leaders can collect, evaluate, and share best practices that promote the efficient and effective operation of cellular therapy programs.
Steering Committee
Chair
Peter Riedell, MD
The University of Chicago Medicine Comprehensive Cancer Center
View All Steering Committee Members
RECUR Initiative
The RECUR initiative is a collaboration among the American Society for Transplantation and Cellular Therapy (ASTCT), AACI, and the Association of Community Cancer Centers (ACCC), aimed at revolutionizing the evaluation process for CAR T therapy to ensure timely and personalized care.
Through the RECUR initiative, ASTCT, AACI, and ACCC aim to empower oncologists, health care professionals, and patients alike with an understanding of the factors necessary for successful CAR T therapy, and the importance of early and timely referral for consultation with a center with expertise. By streamlining the efficiency of the referral process and fostering collaboration among medical experts, this initiative seeks to enhance patient outcomes and expand access to life-saving treatments.
Press release: ASTCT, AACI, and ACCC Launch RECUR Initiative to Enhance Patient Access to CAR T Therapy